More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$9.45B
EPS
-0.7
P/E ratio
--
Price to sales
2.56
Dividend yield
0.323%
Beta
1.222556
Previous close
$60.74
Today's open
$60.66
Day's range
$60.55 - $63.39
52 week range
$32.37 - $66.98
show more
CEO
Frank H. Laukien
Employees
11396
Headquarters
Billerica, MA
Exchange
Nasdaq Global Select
Shares outstanding
152359316
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2026 financial results before market opening on Wednesday, November 4, 2026. The Company will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q3 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A.
Business Wire • Oct 20, 2026

Bruker Gains 66.3% in a Year: What's Driving the Rally?
BRKR shares surge 66.3% in a year, fueled by strong demand in mass spectrometry and biopharma, despite restructuring challenges and currency headwinds.
Zacks Investment Research • Oct 8, 2026

Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution
BERLIN--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. The preprint “A draft atlas of the human plasma proteome at isoform resolution” was posted on September 28, 2026 at https://doi.org/10.64898/2026.09.26.754256. By combining intact protei.
Business Wire • Oct 6, 2026

Why Bruker (BRKR) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research • Oct 2, 2026

Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
SINGAPORE--(BUSINESS WIRE)---- $BRKR #BRKR--At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF dis.
Business Wire • Sep 28, 2026

Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound
Bruker NASDAQ: BRKR CFO Gerald Herman said the company's second-quarter results reflected stronger-than-expected organic order bookings and earnings per share, while revenue came in later than anticipated. He attributed the revenue timing primarily to a mixed demand environment and shipment timing, including semiconductor-metrology orders that are expected to shift into the fourth quarter.
MarketBeat • Sep 26, 2026

Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • Sep 22, 2026

Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley
BERKELEY, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. The investment will enhance access to next-generation NMR technologies, including 800 MHz–class instrumentation. These capabilities strengthen research in chemistry, materials science, structural biology, and related fields across UC Berkeley an.
Business Wire • Sep 21, 2026

Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • Sep 16, 2026

Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking Alpha • Sep 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Bruker Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.